Nonaccruals Improved and Legacy Positions Monetized
Nonaccruals were 2.6% of the total debt portfolio at fair value, down from 3.1% last quarter and 4.6% a year ago. Post-quarter the company sold two legacy nonaccruals (Dominion Diagnostics and All Web Leads). Dominion generated $7 million in cash proceeds versus a $5 million mark as of December 31, 2025.
Stronger Liquidity and Lower Leverage
Available liquidity increased to $671 million (up $100 million q/q) including $51 million cash and $620 million undrawn capacity. Net leverage declined to 1.04x from 1.07x last quarter and remains within the long-term target of 0.9x–1.25x (management plans to run toward the mid- to low end).
Dividend Maintained with Prudent Payout Policy
Board declared a total cash dividend of $0.34 per share; base dividend adjusted to $0.30 per share while supplemental dividend remains at 50% of excess adjusted net investment income above the base, signaling a commitment to shareholder return with conservative leverage.
Attractive New-Deal Yields and Portfolio Yield Stability
Weighted average yield on debt investments was 9.3% (stable q/q). The weighted average yield on new debt investments was 9.2%, ~50 bps higher than the prior quarter. Management noted new private deals pricing at approximately SOFR + 500–550 bps (about 50–100 bps wider than 2025 tights).
Strong Realizations and Reduced ARR Exposure
Proceeds from prepayments, exits and paydowns were $334 million (up from $179 million q/q and $279 million y/y). Notable exit: Mindbody (an ARR software loan) exited at par; ARR exposure fell to 0.76% of fair value from 2.14% last quarter.
Defensive, Diversified Portfolio Construction
84% of portfolio (fair value) is first-lien senior secured debt; average position size is 0.7% of the debt portfolio with no single position >2% of fair value. Median portfolio company EBITDA ~ $182 million; weighted average leverage and interest coverage were 5.2x and 2.1x respectively (consistent with prior quarter).